Introduction

When a child presents with muscle weakness or pain in the hospital, clinicians must differentiate between various causes of myositis and muscle injury. Key entities include infectious myositis (viral or bacterial), idiopathic inflammatory myopathies like juvenile dermatomyositis (JDM) and juvenile polymyositis (JPM), muscle involvement in other connective tissue diseases (CTDs), and rhabdomyolysis. Early differentiation is essential, as treatment varies from supportive care to urgent immunosuppression or surgical intervention. The guide below highlights key clinical features, first-line tests, red flags, and initial management for each condition, with a focus on the inpatient setting.

Viral Myositis (Benign Acute Childhood Myositis)

• Key Clinical Features: Often follows a viral infection, usually influenza (especially influenza B), and presents acutely during the convalescent phase. Children, typically aged 5–9 years old, develop severe bilateral calf pain with a tip-toe gait or refusal to walk, which is disproportionate to other findings. Despite the pain, muscle strength and reflexes remain normal, distinguishing it from true muscle weakness. Usually, there is no rash or joint involvement. Symptoms peak over 1–3 days and usually resolve within a week.
  
• First-Line Diagnostics: Check creatine kinase (CK), which is often elevated but usually only moderately (e.g., 500–3000 U/L). Inflammatory markers (ESR, CRP) are typically normal. A urine dipstick may be positive for blood due to myoglobin but without RBCs on microscopy (myoglobinuria in more severe cases). If the history is classic, extensive imaging or EMG is unnecessary; diagnosis is clinical. However, monitor renal function and urine output in cases of significant CK elevation to screen for rhabdomyolysis.
  
• Red Flags & Clinical Pearls: True weakness (inability to generate force) or absent reflexes are unusual for viral myositis and should prompt evaluation for other diagnoses such as Guillain-Barré or inflammatory myopathy. Additionally, a prolonged course beyond 1 week or worsening of symptoms is not typical and warrants re-evaluation. While benign viral myositis is a common cause of pediatric rhabdomyolysis, it usually has a benign course with low risk of acute kidney injury (AKI). Nonetheless, check urine color—cola-colored urine suggests significant myoglobinuria—and ensure adequate hydration.
  
• Initial Management: Supportive care is usually enough. Ensure vigorous hydration (oral or IV) to prevent AKI. Bed rest or restricted activity until pain subsides. Provide pain relief (acetaminophen); avoid NSAIDs initially if CK is very high or there are kidney concerns. Most cases can be handled with observation and outpatient follow-up if oral intake is good and CK is less than approximately 3000. Admit for IV fluids and monitoring if CK is significantly elevated, the child has poor intake, or shows signs of kidney injury. Expect quick spontaneous improvement; arrange follow-up to confirm CK decrease and symptom resolution.
  

Pyomyositis (Bacterial Myositis)

• Key Clinical Features: Bacterial infection of muscle, commonly caused by Staphylococcus aureus, leads to a localized muscle abscess (pus in muscle). It is more common in tropical regions and among immunocompromised individuals but can also occur in healthy children. Symptoms include fever, ill appearance, and focal muscle pain and swelling. It typically involves large muscle groups such as the thigh, pelvis, or calf, usually unilaterally. On examination, there may be a firm or tender muscle mass; the overlying skin can appear erythematous or warm if the abscess is superficial. Children might have limited use of the affected limb (e.g., limp if a leg muscle is involved) due to pain.
   
• First-Line Diagnostics: Labs often reveal elevated inflammatory markers such as high WBC count, CRP, and ESR due to bacterial infection. CK levels may be normal or only mildly elevated, indicating muscle inflammation and some tissue necrosis. Blood cultures can sometimes detect bacteria. Imaging is essential: an MRI (or ultrasound if MRI is not available) will show muscle inflammation and fluid collection or abscess formation. MRI helps differentiate pyomyositis from other causes of muscle swelling and can confirm an abscess by showing characteristic rim enhancement. If an abscess is identified, aspiration or drainage followed by culture of the abscess fluid confirms the organism and guides antibiotic treatment.
  
• Red Flags & Differentiation: High fever, toxic appearance, focal exquisite tenderness, or a palpable mass strongly suggest pyomyositis rather than other myositis types. Unlike diffuse viral or autoimmune myositis, pyomyositis is usually localized to one muscle group and linked with systemic infection signs. Early on (Stage 1), it might only cause deep muscle pain, so a high suspicion is needed if a child has focal muscle pain with fever. Worsening over 1–3 weeks with a developing fluctuant mass indicates abscess formation (Stage 2). If untreated, it can progress to sepsis (Stage 3), so prompt recognition is essential.
  
• Initial Management: Empiric broad-spectrum antibiotics covering Staph aureus (including MRSA coverage like vancomycin) should be started promptly. If risk factors for Gram-negative or streptococcal infection exist, tailor antibiotics accordingly once cultures result. Surgical or interventional drainage of any confirmed abscess is the mainstay of therapy—either via percutaneous guided drainage or open surgery if needed. In early Stage 1 (phlegmon without abscess), antibiotics alone may suffice, but close monitoring is needed. Provide analgesia and supportive care. Expect to treat with IV antibiotics for at least 1–2 weeks, followed by oral antibiotics to complete a 3–4 week course. Consult orthopedic surgery or interventional radiology for drainage. Monitor for complications such as septic shock, spread to other muscle groups, or osteomyelitis. Improvement in fever and pain should occur within a few days of appropriate therapy, but imaging may be repeated if clinical response is inadequate.

Juvenile Dermatomyositis (JDM)

• Key Clinical Features: Idiopathic inflammatory myopathy characterized by symmetric proximal muscle weakness and characteristic skin findings. Children present with gradually worsening weakness (over weeks to months) in proximal muscles – difficulty climbing stairs, getting up from the floor or a chair, and combing their hair – often accompanied by muscle fatigue and mild pain. Classic skin signs include Gottron’s papules (redish papules over the extensor finger joints), which are distinctive for JDM, and a heliotrope rash (a violet-colored rash around the eyes with eyelid swelling). Other rash features include malar erythema (often in a sun-exposed area on the face), shawl sign (rash over the shoulders and upper back), nailfold capillary changes, “mechanic’s hands” (cracked, thickened skin on the palms and sides of the fingers), and Holster sign (rash on the lateral thigh). JDM is a systemic condition: some patients have low-grade fever, weight loss, or organ involvement (e.g., interstitial lung disease seen in about 75% on imaging, often without symptoms, or gastrointestinal vasculopathy causing abdominal pain). Calcinosis cutis (calcium deposits in the skin) can develop in long-term disease. JDM is rare (about 3 per million children annually) but is the most common pediatric inflammatory myopathy. It mostly affects school-age children, with a peak around age 7, and is more common in females than males.
  
• First-Line Diagnostics: Muscle enzyme labs are the initial step: CK, aldolase, AST, ALT, and LDH are typically elevated due to muscle breakdown. (Note: enzyme levels can be normal in some JDM patients despite active disease, so normal enzymes do not exclude JDM in a classic clinical scenario.) Inflammatory markers (ESR, CRP) may be normal or mildly elevated; a high ESR should prompt evaluation for overlap syndromes or infection since pure JDM often has a normal ESR. Myositis-specific autoantibodies may be present (e.g., anti-NXP2, TIF1γ, MDA5, Mi-2), which can provide prognostic information, but results take time and are not required for initial diagnosis. MRI of the muscle (especially thigh and pelvic girdle muscles) is a valuable, noninvasive tool to detect muscle inflammation and edema. MRI can guide biopsy to the most affected muscle if needed. EMG and muscle biopsy were part of classic diagnostic criteria (Bohan and Peter)—showing myopathic changes and inflammatory infiltrates—but are less often performed in children now. If the diagnosis is unclear or atypical (e.g., no rash), a muscle biopsy can confirm inflammatory myositis and rule out muscular dystrophy. Screen for organ involvement: baseline chest imaging (CXR or CT) if respiratory symptoms (ILD screening), and possibly a swallowing evaluation if dysphagia.
  
• Red Flags & Differentiation: Dermatologic clues are key – Gottron’s papules on extensor joints or the heliotrope periorbital rash distinguish JDM from other myositis causes (other connective tissue diseases like lupus usually lack these specific rashes). Polymyositis (muscle weakness without rash) is extremely rare in young children, so a child with signs of idiopathic myositis is most likely JDM unless proven otherwise. Unlike viral myositis or rhabdomyolysis, JDM causes true muscle weakness rather than just muscle pain – children may struggle with motor tasks but not the intense tenderness seen in viral myositis. If a child has mainly pain and refuses to walk but has normal strength on exam, consider viral myositis; if weakness and rash are present, it is JDM. Dysphagia or respiratory muscle weakness (e.g., diaphragmatic involvement) in JDM are red flags indicating severe disease with risks for aspiration or respiratory failure. JDM can lead to significant complications: aspiration pneumonia, ILD, myocarditis, gastrointestinal vasculitis (which can cause ulceration or perforation). Early aggressive therapy is essential in such cases. Also, unlike adult dermatomyositis, malignancy is very uncommon in JDM, but careful age-appropriate screening is advised if atypical features are observed.
  
• Initial Management: Early involvement of Pediatric Rheumatology is crucial. The mainstay is immunosuppression: High-dose corticosteroids are first-line. In an inpatient with moderate to severe JDM, this often means IV methylprednisolone pulse (e.g., 30 mg/kg up to 1 g daily for 3-5 days), followed by high-dose oral prednisone (1–2 mg/kg/day). Steroids help improve muscle strength and rash; earlier initiation improves outcomes. Along with steroids, methotrexate (MTX) is usually started early as a steroid-sparing agent. For severe or refractory cases, additional therapies include IVIG, cyclosporine, mycophenolate mofetil, or azathioprine. Biologic agents like rituximab are reserved for refractory disease. Supportive care includes physical therapy to maintain range of motion and muscle function, skin care (sun protection to prevent rash flares), and calcium/vitamin D supplementation due to steroid use. If dysphagia is present, implement swallowing precautions or NG feeding as needed. Monitor for calcinosis and promptly treat infections, as immunosuppressed patients are at risk. With treatment, most children improve significantly, although relapses can occur, and about 50% may have ongoing weakness or disability. Early aggressive therapy has reduced mortality to approximately 1–3% in JDM.
  

Polymyositis (Idiopathic Inflammatory Myositis without Dermatitis)

• Key Clinical Features: Polymyositis in children (sometimes called juvenile polymyositis, JPM) is an idiopathic inflammatory myopathy causing muscle weakness without the skin manifestations of dermatomyositis. It is extremely rare in childhood (JDM far predominates pediatric cases). When it occurs (more often in adolescence), it presents very similarly to JDM but without the rash: insidious onset of symmetric proximal muscle weakness (shoulders, hips, neck flexors), difficulty with motor tasks, and muscle fatigue. There is no Gottron’s papule or heliotrope rash. Patients typically do not have the extramuscular vasculopathy seen in JDM (so there is less risk of calcinosis or severe GI involvement), but cardiac or pulmonary muscle involvement (myocarditis or interstitial lung disease) can still occur in polymyositis.
  
• First-Line Diagnostics: The workup is similar to that for JDM: muscle enzymes are elevated (CK, aldolase, AST/ALT, LDH) in most cases, and MRI can reveal muscle inflammation. EMG typically shows characteristic myopathic changes (short-duration, low-amplitude motor unit potentials and fibrillations), supporting an inflammatory myopathy. Because polymyositis is a diagnosis of exclusion, a muscle biopsy is often performed to confirm endomysial inflammation with CD8 T-cells and muscle fiber necrosis, as well as to rule out other conditions such as muscular dystrophies or metabolic myopathies. Autoantibodies (ANA, myositis-specific antibodies) may or may not be present; for example, anti-Jo-1 antibodies are seen in some cases of polymyositis, although they are uncommon in JDM. Screening for underlying causes or associated conditions is recommended; in adults, polymyositis can be paraneoplastic, whereas this is less common in children.
  
• Red Flags & Clinical Pearls: Since true JPM is rare in children, consider other diagnoses if a child does not have the classic rash of JDM. Muscular dystrophies (such as Duchenne MD) can mimic polymyositis (with Gowers’ sign and high CK) but usually appear at younger ages and follow a chronic course from early childhood, without inflammatory signs. In contrast, polymyositis can present in an older child or teenager with a more subacute onset of weakness. Significant muscle pain or tenderness suggests other causes (pain is typically mild in polymyositis). Also, look for signs of an overlap connective tissue disease (see below)—sometimes what appears to be polymyositis is actually an overlap syndrome (e.g., myositis with features of lupus or scleroderma). Inclusion body myositis (IBM), another rash-less myositis, is extremely rare in pediatrics (usually affects those over age 50). If a child’s weakness is distal or asymmetric, or if they do not respond to standard treatment, re-evaluate for other potential diagnoses.
  
• Initial Management: Management mirrors that of JDM: start high-dose corticosteroids (e.g., prednisone 1 mg/kg/day or IV pulses for severe weakness) as early as possible. Add an immunosuppressive DMARD (methotrexate or azathioprine) to help achieve and maintain remission. Physical therapy and rehabilitation are important to recover muscle strength. If response is inadequate, IVIG or second-line immunosuppressants (mycophenolate, cyclosporine) can be tried, and rituximab in refractory cases (based on adult data). Involve rheumatology for guidance. Monitor pulmonary function if there’s any suggestion of ILD or respiratory muscle weakness, and conduct cardiac evaluations (ECG, echo) if myocarditis is suspected. Prognosis: Juvenile polymyositis, once confirmed, generally responds to therapy similarly to JDM, though data are limited due to its rarity. Ensure long-term follow-up as relapse can occur if medications are tapered too quickly.

Myositis in Idiopathic Connective Tissue Diseases (Overlap Syndromes)

• Key Clinical Features: Pediatric systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), juvenile systemic sclerosis, and other connective tissue diseases (CTDs) can all feature muscle inflammation as part of an overlap syndrome. In these cases, muscle weakness is usually mild to moderate compared to classic juvenile dermatomyositis (JDM), with other systemic features being more prominent. For instance, a child with lupus overlap myositis may exhibit proximal muscle weakness along with malar rash, arthritis, nephritis, or cytopenias. MCTD (characterized by U1-RNP antibody) often presents with signs of lupus, myositis, and scleroderma combined. In scleroderma-myositis overlap, children may show skin tightening (sclerodactyly) along with muscle weakness. Importantly, these patients do not have Gottron’s papules or heliotrope rash; any rash seen will be typical of the underlying CTD (for example, lupus rash generally spares the knuckles, unlike Gottron’s sign). The onset can be chronic or subacute—sometimes myositis appears after years of diagnosed CTD, or it may occur simultaneously at presentation. Clues such as Raynaud’s phenomenon, swollen joints, specific rashes, or organ involvement (kidney, lung) suggest a broader CTD rather than isolated JDM.
  
• First-Line Diagnostics: The workup aims to confirm muscle involvement and identify the underlying disease. Muscle enzymes (like CK) may be elevated, but often not as much as in primary myositis. Autoantibody profiles are essential: a positive ANA with antibodies to DNA, RNP, Smith, etc., might suggest lupus or MCTD. Conversely, JDM usually shows a negative ANA or a positive result with myositis-specific antibodies. Check for involvement of other organs: for example, renal function and urinalysis for lupus nephritis, pulmonary function tests or imaging for ILD, and cardiac assessments if myocarditis is a concern. A muscle biopsy in overlap myositis may reveal inflammatory changes; in lupus myositis, histology can show lymphocytic infiltration and sometimes muscle fiber necrosis without the capillary changes typical of JDM. Ultimately, diagnose or confirm the CTD: for instance, apply ACR/EULAR criteria for SLE if clinical features align, since muscle weakness might be part of a multi-system illness.
  
• Red Flags & Differentiation: Overlap myositis should be suspected if a child’s myositis presents with prominent extra-muscular features not explained by dermatomyositis. For example, significant arthritis, high fever, and organ inflammation (such as serositis or nephritis) are more typical of systemic JIA or SLE than JDM. Additionally, the absence of classic JDM skin findings combined with other autoimmune markers (e.g., double-stranded DNA antibody for lupus or scleroderma changes) are important clues. In juvenile SLE, true polymyositis is uncommon; myositis occurs in a minority of cases and usually along with other lupus features. If a patient with a known CTD develops muscle weakness, distinguish medication side effects (such as steroid-induced myopathy, which causes weakness with normal CK) from active myositis—active myositis will have elevated CK and signs of inflammation. Myasthenia gravis is another cause of weakness in CTD but causes fatigable, not constant, weakness, and normal CK.
  
• Initial Management: The main approach is treating the underlying CTD, often with immunosuppressive therapy that also addresses myositis. For example, juvenile SLE with myositis would be treated with high-dose corticosteroids (which treat both lupus and muscle inflammation) and possibly other agents like azathioprine or mycophenolate for lupus maintenance. MCTD or overlap syndrome patients might receive methotrexate (MTX) or cyclophosphamide depending on organ involvement. In all cases, if muscle involvement is significant and affects function, high-dose steroids are initially recommended, similar to JDM management. Physical therapy and rehabilitation are essential for recovering muscle strength once acute inflammation subsides. Consultation with pediatric rheumatology is advised for guidance on immunosuppressive regimens tailored to the specific CTD (for instance, adding hydroxychloroquine in SLE, or IVIG if overlapping with dermatomyositis features). The child should be monitored for both muscle improvement and control of the systemic disease. Often, overlap myositis improves as the overall disease is managed, but refractory cases may require therapies used in primary myositis (e.g., IVIG or rituximab). Close monitoring for steroid side effects or complications of multi-organ disease is necessary during inpatient care.
  

Rhabdomyolysis

• Key Clinical Features: Rhabdomyolysis involves rapid muscle fiber necrosis that releases intracellular contents like myoglobin and electrolytes into the bloodstream. It can result from severe overuse or exertion, trauma such as compression or crush injuries, toxins or drugs, metabolic disorders, or infections. In children, viral myositis is the most common cause of rhabdomyolysis, often called “benign acute childhood myositis” when mild. Symptoms typically include generalized muscle pain and tenderness, especially in the thighs and calves, weakness, and dark brown (“tea-colored” or “cola-colored”) urine due to myoglobinuria. Some children may experience muscle swelling and, if compartment syndrome develops, tense and painful compartments. Systemic signs like fever may be present if infection or heat stroke is the trigger, but many cases only show malaise and muscle symptoms. A key distinguishing feature: in pure rhabdomyolysis, there is no primary inflammation, so rashes and joint or skin involvement are usually absent unless trauma is involved. Neurologic exam may reveal reduced strength if muscles are significantly injured, but reflexes are typically preserved unless nerve compression from swelling occurs.
  
• First-Line Diagnostics: Serum CK is significantly elevated – often more than 5 times the upper limit of normal, and in severe cases, frequently exceeds 5000–10,000 U/L. This high CK level helps differentiate rhabdomyolysis from milder inflammatory myositis, where CK is typically lower. Urine analysis usually shows positive for heme (myoglobin), and confirmatory testing for urine myoglobin can be performed. Blood tests often reveal electrolyte imbalances: hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia (due to calcium influx into muscles) as cells break down. Renal function should be closely monitored through BUN and creatinine levels, since myoglobin can cause acute kidney injury. Additional tests include elevated AST/ALT (released from muscle) and high LDH. If the cause is unclear, screening for potential causes such as infection (viral PCR, cultures), toxicology screens for drugs, and metabolic evaluations in recurrent cases (including inborn errors of metabolism or enzyme deficiencies) is recommended. In rhabdomyolysis, EMG and muscle biopsy are not indicated acutely—they would show nonspecific muscle fiber necrosis without inflammatory infiltrate. Imaging is determined by the underlying cause, such as MRI if there is concern for compartment syndrome or deep muscle necrosis, but it is not used routinely.
  
• Red Flags & Clinical Pearls: The combination of extremely high CK and myoglobinuria with muscle pain disproportionate to weakness suggests rhabdomyolysis. Watch for early signs of complications: arrhythmias caused by hyperkalemia (peaked T-waves, etc.), which can develop rapidly as potassium is released from damaged muscle; and acute kidney injury (rising creatinine, decreased urine output), usually occurring 12–72 hours after muscle injury. In an inpatient setting, continuous cardiac monitoring is advised for severe rhabdomyolysis due to electrolyte risks. Compartment syndrome is another red flag—if a muscle group is very swollen and tense with decreasing distal pulses or sensation, urgent evaluation for fasciotomy is necessary. Differentiate rhabdomyolysis from inflammatory myositis: in rhabdomyolysis, muscle cell membranes are broken, causing cell contents to leak, whereas in myositis, the cells remain intact but are damaged by the immune system. Therefore, rhabdomyolysis often presents with more systemic signs (fever if sepsis, arrhythmia risk, shock in severe cases) and lacks chronic rash or autoimmune features. Another key point: gross hematuria versus myoglobinuria—if urine dipstick tests positive for blood but microscopic exam shows no RBCs, think of myoglobin from rhabdomyolysis. If a child has recurrent rhabdomyolysis with exercise or fasting, consider a metabolic myopathy (e.g., glycogen storage or fatty acid oxidation disorder) and refer to neuromuscular specialists.
  
• Initial Management: Rapid, aggressive fluid resuscitation is essential. Start IV fluids (e.g., 0.9% saline boluses followed by high-volume maintenance) to promote myoglobin clearance and protect kidney function. Aim for a high urine output and monitor hourly. In severe cases, consider urine alkalinization (adding bicarbonate to IV fluids) to reduce myoglobin toxicity in the kidneys, and/or use mannitol as an osmotic diuretic if compartment syndrome is absent. Correct electrolyte imbalances: administer calcium for hyperkalemia if EKG changes occur; use insulin and glucose to drive K⁺ into cells, etc. Avoid nephrotoxic drugs (e.g., NSAIDs, certain antibiotics) during acute management. If compartment syndrome is suspected (pain out of proportion, tense swelling), seek surgical consultation immediately for possible fasciotomy. Treat the underlying cause: use appropriate antimicrobials if caused by infection; control seizures or agitation if related to neuroleptic malignant syndrome; initiate cooling for heat stroke. Most pediatric viral rhabdomyolysis cases resolve with fluids and rest, and AKI is uncommon, but renal function and electrolytes should be checked frequently (often every 4–6 hours in the early phase). In ICU-level rhabdomyolysis, consider continuous renal replacement therapy (dialysis) if severe AKI or life-threatening hyperkalemia develops. Once stabilized and CK levels are trending down, gradually resume activity. Monitor CK levels daily—peak levels followed by a downward trend indicate improvement. Educate the family on hydration and avoiding triggers (for exertional rhabdo, recommend gradual training; for recurrent viral rhabdo, emphasize hydration during illness, etc.).
  

Comparison of Key Features by Diagnosis

Each of these conditions requires a tailored approach in the hospital. By recognizing the distinguishing clinical patterns – such as the rash of JDM, the focal abscess of pyomyositis, the dramatic CK elevation of rhabdo, or the multi-system features of a CTD overlap – the pediatric team can initiate the appropriate diagnostic workup and management promptly. Early differentiation and treatment are crucial to improve outcomes and prevent complications in pediatric myositis cases.